Skip to main content
SpringerLink
Log in

Clean sweep for apixaban in atrial fibrillation

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. funded by Pfizer and Bristol Myers Squibb

References

  1. Dorian P, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. European Heart Journal : 9 Feb 2014. Available from: URL: http://doi.org/10.1093/eurheartj/ehu006

    PubMed  Google Scholar 

  2. Lip GY, et al. Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Clinical Therapeutics : 5 Feb 2014. Available from: URL: http://doi.org/10.1016/j.clinthera.2013.12.011

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clean sweep for apixaban in atrial fibrillation. PharmacoEcon Outcomes News 697, 4 (2014). https://doi.org/10.1007/s40274-014-1064-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1064-z

Search

Navigation